Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis
Open accessAbstract
Although serum prostate specific antigen (PSA) is a well-established diagnostic tool for prostate cancer (PCa) detection, the definitive diagnosis of PCa is based on the information contained in prostate needle biopsy (PNBX) specimens. To define the proteomic features of PNBX specimens to identify candidate biomarkers for PCa, PNBX specimens from patients with PCa or benign prostatic hyperplasia (BPH) were subjected to comparative proteomic analysis. 2-DE revealed that 52 protein spots exhibited statistically significantly changes among PCa and BPH groups. Interesting spots were identified by MALDI-TOF-MS/MS. The 2 most notable groups of proteins identified included latent androgen receptor coregulators [FLNA(7-15) and FKBP4] and enzymes involved in mitochondrial fatty acid beta-oxidation (DCI and ECHS1). An imbalance in the expression of peroxiredoxin subtypes was noted in PCa specimens. Furthermore, different post-translationally modified isoforms of HSP27 and HSP70.1 were identified. Importantly, changes in FLNA(7-15), FKBP4, and PRDX4 expression were confirmed by immunoblot analyses. Our results suggest that a proteomics-based approach is useful for developing a more complete picture of the protein profile of PNBX specimen. The proteins identified by this approach may be useful molecular targets for PCa diagnostics and therapeutics.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
FKBP52 is overexpressed in prostate cancer patients.
“Because FKBP52 is overexpressed in prostate cancer patients [27], it is feasible that overexpression of FKBP52 could be the cause of increased AR co-activation by β-catenin in prostate cancer.”
From The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling (2015) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Jemal, A., Siegel, R. L., Ward, E. M., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,309 · see citing works
Self-citationNEUHOFF, V., Arold, N., Taube, D., & Ehrhardt, W. (1988) · Electrophoresis · doi:10.1002/elps.1150090603 · Cited by 2,676 · see citing works
Structure, mechanism and regulation of peroxiredoxins
Wood, Z. A., Schröder, E., Harris, J. R., & Poole, L. B. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)00003-8 · Cited by 2,546 · see citing works
Yan, J. X., Wait, R., Berkelman, T., Harry, R. A., Westbrook, J. A., Wheeler, C., & Dunn, M. J. (2000) · Electrophoresis · doi:10.1002/1522-2683(200011)21:17 · Cited by 705 · see citing works
The dynamic range of protein expression: A challenge for proteomic research
Corthals, G. L., Wasinger, V. C., Hochstrasser, D. F., & Sanchez, J. (2000) · Electrophoresis · doi:10.1002/(sici)1522-2683(20000401)21:6 · Cited by 615 · see citing works
The many faces of filamin: A versatile molecular scaffold for cell motility and signalling
Feng, Y., & Walsh, C. A. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1034 · Cited by 506 · see citing works
Pathological and molecular aspects of prostate cancer
Marzo, A. M. D., Nelson, W. G., Isaacs, W. B., & Epstein, J. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12779-1 · Cited by 471 · see citing works
Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford, P. A., Dodson, A. R., PARSONS, K. F., DESMOND, A. D., Woolfenden, A., Fordham, M., Neoptolemos, J. P., Ke, Y., & Foster, C. S. (2000) · PubMed · Cited by 365 · see citing works
Rocchi, P., So, A., Kojima, S., Signaevsky, M., Beraldi, E., Fazli, L., Hurtado‐Coll, A., Yamanaka, K., & Gleave, M. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3998 · Cited by 318 · see citing works
Decrease and Gain of Gene Expression Are Equally Discriminatory Markers for Prostate Carcinoma
Ernst, T., Hergenhahn, M., Kenzelmann, M., Cohen, C. D., Bonrouhi, M., Weninger, A., Klären, R., Gröne, E. F., Wiesel, M., Güdemann, C., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61165-0 · Cited by 258 · see citing works
Screening for Prostate Cancer with Prostate-Specific Antigen — An Examination of the Evidence
Woolf, S. H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511233332107 · Cited by 242 · see citing works
Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma
Kinnula, V. L., Lehtonen, S. T., Sormunen, R. T., Kaarteenaho–Wiik, R., Kang, S. W., Rhee, S. G., & Soini, Y. (2002) · The Journal of Pathology · doi:10.1002/path.1042 · Cited by 233 · see citing works
Peroxiredoxins in breast carcinoma.
Karihtala, P., Mäntyniemi, A., Kang, S. W., Kinnula, V. L., & Soini, Y. (2003) · PubMed · Cited by 232 · see citing works
Kim, H., Lee, T., Park, E. S., Suh, J. M., Park, S. J., Chung, H. K., Kwon, O., Kim, Y. K., Ro, H. K., & Shong, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.24.18266 · Cited by 226 · see citing works
Filamin A: phenotypic diversity
Robertson, S. P. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.04.001 · Cited by 214 · see citing works
Physiological role for the cochaperone FKBP52 in androgen receptor signaling
Cheung-Flynn, J., Prapapanich, V., Cox, M. B., Riggs, D. L., Suarez-Quian, C., & Smith, D. F. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0071 · Cited by 212 · see citing works
Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions
Loy, C. J., Sim, K. S., & Yong, E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0736237100 · Cited by 202 · see citing works
Quantifying Protein in 2-D PAGE Solubilization Buffers
Ramagli, L. S. (2003) · Humana Press eBooks · doi:10.1385/1-59259-584-7:99 · Cited by 199 · see citing works
Hjälm, G., Macleod, J., Kifor, O., Chattopadhyay, N., & Brown, E. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100784200 · Cited by 191 · see citing works
Subcellular localization and physiological role of α-methylacyl-CoA racemase
Ferdinandusse, S., Denis, S. W., IJlst, L., Dacremont, G., Waterham, H. R., & Wanders, R. J. A. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31983-0 · Cited by 183 · see citing works
P504S/α-Methylacyl-CoA Racemase
Jiang, Z., Wu, C., Woda, B. A., Dresser, K., Xu, J., Fanger, G. R., & Yang, X. J. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200209000-00007 · Cited by 170 · see citing works
Self-citationPeroxisomal branched chain fatty acid ?-oxidation pathway is upregulated in prostate cancer
Zha, S., Ferdinandusse, S., Hicks, J. L., Denis, S. W., Dunn, T. A., Wanders, R. J. A., Luo, J., Marzo, A. M. D., & Isaacs, W. B. (2004) · The Prostate · doi:10.1002/pros.20177 · Cited by 164 · see citing works
The Differential Proteome Profile of Stomach Cancer: Identification of the Biomarker Candidates
Jang, J. S., Cho, H. Y., Lee, Y. J., et al. (2004) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/0965040042380441 · Cited by 163 · see citing works
Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus
Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., & Pratt, W. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402223200 · Cited by 150 · see citing works
Liu, G., Thomas, L., Warren, R. A., Enns, C. A., Cunningham, C. C., Hartwig, J. H., & Thomas, G. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.7.1719 · Cited by 139 · see citing works
From Cytoprotection to Tumor Suppression: The Multifactorial Role of Peroxiredoxins
Butterfield, L. H., Merino, A., Golub, S. H., & Shau, H. (1999) · Antioxidants and Redox Signaling · doi:10.1089/ars.1999.1.4-385 · Cited by 137 · see citing works
Varma, M., & Jasani, B. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02188.x · Cited by 135 · see citing works
Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer
Meehan, K. L., Holland, J. W., & Dawkins, H. J. S. (2001) · The Prostate · doi:10.1002/pros.10032 · Cited by 120 · see citing works
Yokoyama, Y., Kuramitsu, Y., 高島, 元., et al. (2004) · PROTEOMICS · doi:10.1002/pmic.200300712 · Cited by 116 · see citing works
Androgens target prohibitin to regulate proliferation of prostate cancer cells
Gamble, S. C., Odontiadis, M., Waxman, J., Westbrook, J. A., Dunn, M. J., Wait, R., Lam, E. W. ‐., & Bevan, C. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207444 · Cited by 114 · see citing works
Davies, T. H., & Sánchez, E. R. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.03.013 · Cited by 109 · see citing works
Androgen Receptor Coregulators in Prostate Cancer
Rahman, M. M., Miyamoto, H., & Chang, C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0746-3 · Cited by 103 · see citing works
Gopalakrishnapillai, A., Rajasekaran, S. A., Wang, S., Hankinson, O., Bander, N. H., & Rajasekaran, A. K. (2003) · PubMed · Cited by 97 · see citing works
Quan, C., Cha, E., Lee, H.-L., Han, K. H., Lee, K. M., & Kim, W. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(05)00659-2 · Cited by 96 · see citing works
Automatic Poisson peak harvesting for high throughput protein identification
Breen, E. J., Hopwood, F. G., Williams, K. L., & Wilkins, M. R. (2000) · Electrophoresis · doi:10.1002/1522-2683(20000601)21:11 · Cited by 89 · see citing works
Edwards, J., Anderson, N. G., Tollaksen, S. L., et al. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.1.160 · Cited by 68 · see citing works
Proteomic analysis of protein expression in prostate cancer.
Lexander, H., Palmberg, C., Auer, G., et al. (2005) · PubMed · Cited by 57 · see citing works
Hwa, J. S., Park, H., Jung, J. H., et al. (2005) · Journal of Korean Medical Science · doi:10.3346/jkms.2005.20.3.450 · Cited by 50 · see citing works
Janßen, U., Davis, E. M., Beau, M. M. L., & Stoffel, W. (1997) · Genomics · doi:10.1006/geno.1996.4597 · Cited by 50 · see citing works
Taylor, J. A., Gancarczyk, K. J., Fant, G. V., et al. (2002) · Urology · doi:10.1016/s0090-4295(02)01878-2 · Cited by 46 · see citing works
H�ggstr�m, S., Bergh, A. R. J., & Damber, J. (2000) · The Prostate · doi:10.1002/1097-0045(20000915)45:1 · Cited by 39 · see citing works
Improved Biomarkers for Prostate Cancer: A Definite Need
Carter, H. B., & Isaacs, W. B. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh174 · Cited by 24 · see citing works
Prostate–Specific Antigen Complexed to α1–Antichymotrypsin in the Early Detection of Prostate Cancer
nez, M. M. I., a, F. E. N., Royo, M., et al. (2000) · European Urology · doi:10.1159/000020257 · Cited by 18 · see citing works
β‐Oxidation of unsaturated fatty acids in humans Isoforms of Δ3, Δ2‐enoyl‐CoA isomerase
Kilponen, J. M., & Hiltunen, J. K. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81590-v · Cited by 15 · see citing works
Evidence for downregulation of calcium signaling proteins in advanced mouse adenocarcinoma
Ruddat, V. C., Whitman, S., Klein, R. D., Fischer, S. M., & Holman, T. R. (2005) · The Prostate · doi:10.1002/pros.20207 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 7
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun M. Can- cer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
- Yang L, Li L, Chen Y, Parkin DM. Cancer incidence and mortality estimates and prediction for year 2000 and 2005 in China. Chinese J Health Stat 2005;22:218-32.
- Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF III, Emmert-Buck MR. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell. Electrophoresis 2000;21:2235-42.
- Davies TH, Sanchez ER. FKBP52. Int J Biochem Cell Biol 2005; 37:42-4.
- Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxir- edoxins in breast carcinoma. Clin Cancer Res 2003;9:3418-24.
- Sarto C, Binz PA, Mocarelli P. Heat shock proteins in human cancer. Electrophoresis 2000;21:1218-26.
- Gibbons NB, Watson RW, Coffey RN, Brady HP, Fitzpatrick JM. Heat-shock proteins inhibit induction of prostate cancer cell apopto- sis. Prostate 2000;45:58-65.
Cited by
Sorted by citations
FKBP51 and FKBP52 in signaling and disease
Storer, C. L., Dickey, C. A., Galigniana, M. D., Rein, T., & Cox, M. B. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.08.001 · Cited by 266 · see citing works
“The prostate dysgenesis observed in 52KO mice established FKBP52 as a critically important regulator of prostate development [7], and enhanced FKBP52 levels have been observed in prostate needle biopsies from human patients [52].”
Regulation of steroid hormone receptor function by the 52-kDa FK506-binding protein (FKBP52)
Sivils, J. C., Storer, C. L., Galigniana, M. D., & Cox, M. B. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.03.010 · Cited by 81 · see citing works
Bracher, A., Kozany, C., Hähle, A., Wild, P., Zacharias, M., & Hausch, F. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.07.041 · Cited by 45 · see citing works
Emerging proteomics biomarkers and prostate cancer burden in Africa
Adeola, H. A., Blackburn, J. M., Rebbeck, T. R., & Zerbini, L. F. (2017) · Oncotarget · doi:10.18632/oncotarget.16568 · Cited by 26 · see citing works
The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling
Storer Samaniego, C., Suh, J. H., Chattopadhyay, A., Olivares, K., Guy, N., Sivils, J. C., Dey, P., Yumoto, F., Fletterick, R. J., Strom, A. M., et al. (2015) · PLOS One · doi:10.1371/journal.pone.0134015 · Cited by 13 · see citing works
“Because FKBP52 is overexpressed in prostate cancer patients [27], it is feasible that overexpression of FKBP52 could be the cause of increased AR co-activation by β-catenin in prostate cancer.”
Background
- Authors
- Lin, J., Xu, J., Tian, H., Gao, X., Chen, Q., Gu, Q., Xu, G., Song, J., & Zhao, F.
- Affiliations
- Huadong Hospital (CN)
- Chinese Academy of Sciences (CN)
- Xiamen University (CN)
- Zhejiang Sci-Tech University (CN)
- Corresponding author
- Gu, Qi
- Zhao, Fu‐kun
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2007-08-23
- Volume
- 121
- Issue
- 12
- Pages
- 2596-2605
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2087839294
- Cited by
- 125
- References
- 45
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 6 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 7 · 2016: 5 · 2015: 13 · 2014: 9 · 2013: 7 · 2012: 10
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Keywords
- prostate cancer, prostate needle biopsy, tumor markers, benign prostatic hyperplasia, proteomic profiling, FKBP4, mitochondrial beta-oxidation, DCI, ECHS1, peroxiredoxin, HSP27, HSP70, post-translational modification, peroxiredoxin 4
- MeSH terms
- Biopsy, Needle, Contractile Proteins, Feasibility Studies, Heat-Shock Proteins, Humans, Male, Microfilament Proteins, Neoplasm Proteins, Prostatic Hyperplasia, Prostatic Neoplasms, Biomarkers, Tumor, Immunoblotting, Electrophoresis, Gel, Two-Dimensional, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Molecular Chaperones, HSP70 Heat-Shock Proteins, Tacrolimus Binding Proteins, Proteomics, Peroxiredoxins, HSP27 Heat-Shock Proteins, Filamins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
